Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 have shown good efficacy in cancer treatment by enhancing T-cell activation4,5; nevertheless, only a minority of patients derive benefits due to the intratumoral insufficiency of both T cells and injected PD-1/PD-L1 inhibitors6–8. Here, CD274 is linked to cancer.